Baricitinib is a selective JAK1/JAK2 inhibitor that dampens cytokine-driven inflammatory signalling, used for rheumatoid arthritis, severe COVID-19 pneumonia and alopecia areata. Simson Pharma's Baricitinib reference standard and impurities support stability-indicating method development across this expanding range of indications.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Baricitinib Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.